Venmax Drugs and Pharmaceuticals Limited is a Hyderabad-based public limited company (CIN: **L24230TG1988PLC009102**) listed on **BSE Limited**. Historically focused on the trading of pharmaceutical products, the company is currently undergoing a fundamental strategic pivot toward integrated manufacturing. VDPL specializes in **Active Pharmaceutical Ingredients (APIs)**, **drug intermediates**, **bulk drugs**, and **biotech products**. --- ### **Strategic Transformation: The Hatri Pharma Amalgamation** VDPL is executing a high-impact transition from a trading-centric model to a vertically integrated manufacturing entity through a **Scheme of Arrangement** and merger with **Hatri Pharma Private Limited (HPPL)**. * **Vertical Integration:** The merger with HPPL, a specialist in drug intermediates and fine chemicals, is designed to secure the supply chain and improve operating margins by internalizing production. * **Manufacturing Footprint:** The acquisition brings HPPL’s manufacturing facilities in the **Nellore District, Andhra Pradesh**, into the VDPL portfolio. * **Synergies and Scale:** Management aims to achieve **economies of scale** through backward integration, optimized capacity utilization, and the ability to **cross-sell** across expanded distribution channels. * **Intellectual Property:** The structural transition ensures the transfer of all **trade names, marks, brands, patents, and intellectual property** to the combined entity to maintain commercial goodwill. * **Share Exchange Ratio:** VDPL will allot **1 (One) Equity Share** for every **1 (One) Equity Share** held by HPPL shareholders. --- ### **Capital Structure and Fund Raising** To facilitate the merger and fund its manufacturing ambitions, the company has aggressively expanded its financial base. | Metric | Status / Target Value | | :--- | :--- | | **Authorised Share Capital (Pre-2025)** | **₹8,00,00,000** | | **Authorised Share Capital (Current)** | **₹60,00,00,000** (Approved Sept 2025) | | **Paid-up Share Capital (as of March 2026)** | **₹11,58,29,300** | | **Post-Merger Issued Capital (Estimated)** | **₹38,99,39,300** | | **Preferential Allotment (Jan 2025)** | **1,60,00,000 Warrants** at **₹20** each | | **Total Fund Raising Target (Warrants)** | **₹32,00,00,000** | | **Warrant Conversion Price** | **₹20** (₹10 Face Value + ₹10 Premium) | As of **March 27, 2026**, **63,44,000** warrants have been converted into equity shares, with **36,81,000** warrants remaining pending for conversion. --- ### **Financial Performance and Operational Model** VDPL operates under a **single reportable segment** ("Drugs") in accordance with **Ind AS 108**. After a period of stagnant activity, the company reported a return to operational turnover in **FY 2024-25**. **Financial Snapshot (₹ in Lakhs):** | Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :---: | :---: | :---: | | **Total Sales** | **80.73** | **0.00** | **41.93** | | **Other Income** | **105.32** | **19.86** | - | | **Total Income** | **186.05** | **19.86** | **41.93** | | **Total Expenses** | **187.46** | **11.17** | - | | **Profit/(Loss) After Tax** | **(1.05)** | **6.45** | **22.56** | * **Dividend Policy:** No dividend was recommended for **FY 2024-25** due to the net loss and capital preservation requirements. * **Asset Management:** Property, Plant, and Equipment (PPE) undergo physical verification on a **three-year cycle**. * **Auditors:** **M/s. PPKG & Co**, Chartered Accountants, are appointed as Statutory Auditors for the **2023-2028** term. --- ### **Growth Drivers and Market Positioning** * **Leadership Transition:** **Mr. Venkata Rao Sadhanala** has been appointed as **Managing Director** (effective March 2026 for 5 years), bringing **30 years** of experience in corporate strategy and M&A to lead the post-merger entity. * **Sector Tailwinds:** The company is positioning itself to capture the Indian pharmaceutical sector's projected **CAGR of 7.5-10.5% (2023-27)** and the global consumer healthcare market growth of **~6% annually**. * **Technological Modernization:** Post-merger plans include enhancing **mechanization and automation** to improve production efficiency. * **Diversification:** Moving beyond trading in **Nutraceuticals** and **Cosmetic Chemicals** into the high-value manufacturing of **Drug Intermediates**. --- ### **Critical Risk Factors and Regulatory Challenges** Investors should note significant regulatory and governance hurdles that the company is currently working to resolve. **1. Listing and Compliance Defaults:** * **Trading Suspension:** VDPL shares on the **BSE** are currently suspended due to non-payment of **Annual Listing Fees** and other penal reasons. * **MCA "In-active" Status:** The company is marked as **"In-active"** on the Ministry of Corporate Affairs portal due to the non-filing of **e-form INC-22A**. * **Filing Backlog:** Due to the inactive status, the company has been unable to file **AOC-4** (Financial Statements) and **MGT-7** (Annual Returns). **2. Governance Gaps:** * **Board Composition:** The Board currently lacks a proper balance of **Executive, Non-Executive, and Independent Directors**. * **Key Vacancies:** There are currently no appointed **Company Secretary**, **Internal Auditor**, or **Woman Director**. * **Leadership Continuity:** The formal term of the previous Managing Director ended in **August 2021**, though new appointments are now underway. **3. Legal and Industry Framework:** The company operates under a stringent regulatory environment. Compliance with the following is critical for operational continuity: | Category | Key Applicable Laws | | :--- | :--- | | **Pharma Specific** | **Drugs & Cosmetics Act, 1940**; **Pharmacy Act, 1948**; **NDPS Act, 1985** | | **Environmental** | **Environment Protection Act, 1996**; **Hazardous Waste Rules, 2016** | | **Labor/Social** | **Factories Act, 1948**; **EPF Act, 1952**; **ESI Act, 1948**; **Minimum Wages Act** | **4. Financial Risks:** * **Market Volatility:** Exposure to **interest rate risk** and **currency risk**, particularly regarding the cost of raw materials denominated in foreign currencies. * **Tax Neutrality:** The merger must remain compliant with **Section 2(1B) of the Income Tax Act, 1961** to ensure tax-neutral status.